Navigation Links
How tumor cells move
Date:4/8/2009

If cancer cells lack a certain protein, it could be much easier for them to penetrate healthy body tissue, the first step towards forming metastases. Scientists at the Pharmacology Institute of the University of Heidelberg have discovered the previously unknown cell signal factor SCAI (suppressor of cancer cell invasion), which inhibits the movement and spread of tumor cells in laboratory tests. When the factor's functioning was disrupted, the cancer cells moved much more effectively in what are known as three-dimensional matrix systems, which imitate some of the tissue properties of the human body.

"The protein is apparently suppressed in many types of tumors, e.g. breast, lung, or thyroid," explains Dr. Robert Grosse, head of the Emmy Noether Junior Research Group funded by the German Research Association (DFG) at the Pharmacology Institute. The new factor could be an interesting starting point for research into new mechanisms for fighting cancer. The research team's results have now been published online in the prestigious international journal Nature Cell Biology.

Focus on particularly aggressive cancers

Tumor cells are extremely mobile and "adept" at penetrating healthy tissue to form metastases. They adapt to the consistency of the respective tissue by changing their shapes constantly and attach flexibly to surrounding tissues during movement with the help of special surface structures (receptors).

One of these receptors is what is known as b1-integrin, which is frequently formed in many tumors such as metastasizing breast cancer. "The cell signal factor SCAI controls the formation and function of b1-integrin," says Dr. Robert Grosse. "If there is too little SCAI in tumor cells, then b1-integrin is overactive, so to speak. The cell can change more rapidly to a more aggressive form and penetrate surrounding tissue, a crucial step toward increased spreading of the tumor and the possible formation of metastases."

In their recently published study, the Heidelberg researchers examined cells from skin cancer (melanoma) and breast cancer. In other projects, Dr. Robert Grosse's team would like to study the function of the signal factor SCAI more closely in an animal model. "If the function of SCAI is confirmed to be decisive in the formation of especially aggressive tumor cells, this could be a promising starting point for developing new diagnostic methods or medication," says the pharmacologist. It could also be possible to develop an agent that prevents the genetic suppression of the signal factor in cancer cells. But first the researchers need to better understand how the signal factor itself is regulated in the cell.


'/>"/>

Contact: Dr. Robert Grosse
robert.grosse@pharma.uni-heidelberg.de
49-062-215-48619
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. University of Kansas graduate student researcher takes aim at deadly brain tumors
2. Skin cancer study uncovers new tumor suppressor gene
3. Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
4. New tumor markers determine therapy intensity
5. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
6. Tiny tool to control growing blood vessels opens new potential in tumor research
7. Researchers isolate protein domain linked to tumor progression
8. Singapore research organisations team up to advance drug discovery using brain tumor stem cells
9. Scattered light rapidly detects tumor response to chemotherapy
10. New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome
11. Stress may hasten the growth of melanoma tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm ... its continued commitment to the advancement of the clinical trials segment. Hosted in ... to clinical trial planning and management. , As executive talent specialists in ...
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights law ... into whether the board members of CoLucid Pharmaceuticals, Inc. ... in connection with the proposed sale of the Company ... company that develops small molecules for the acute treatment ... announced it had signed a definitive merger agreement with ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC ... to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates ... Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal delta” method ...
Breaking Biology Technology: